1M6MYTD1A5AMAX
Chargement des cours...
Prévisions
| Acheter |
0 |
| Conserver |
1 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Predictive Oncology approves increase to equity incentive plan and issuance of pre‑funded warrants
At the annual meeting, shareholders voted to increase the 2024 Equity Incentive Plan by 1,000,000 shares and to issue 14,903,393 common shares that will be issued upon exercise of pre‑funded warrants. The elections of directors Daniel E. Handley and Chuck Nuzum were confirmed and KPMG was appointed as independent auditors. Predictive Oncology also reported a significant net loss in Q3 2025, but said it has regained compliance with NASDAQ’s minimum stockholders’ equity requirement and is pursuing initiatives to enter the AI infrastructure market. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 2,82 M | 123 699,49 % |
| Bénéfice brut | 176,69 k | 1 440,23 % |
| Bénéfice net | -15,08 M | 758,24 % |
| EBITDA | -3,52 M | 129,57 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 103,67 M € |
Nombre d'actions | 11,49 M |
Plus haut/bas sur 52 semaines | 27,71 € - 0,89 € |
| Dividendes | Non |
Bêta | 3,47 |
Ratio P/E | -0,07 |
Ratio PEG | 0,00 |
Ratio P/B | 6,04 |
Ratio P/S | 36,82 |
Profil de l'entreprise
| Nom | Predictive Oncology |
| PDG | Christopher Miglino |
| Employés | 14 |
Découvrir des actifs
Les actionnaires de Predictive Oncology investissent également dans les actifs suivants
